Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.75 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.66 |
| ▸ | PDE4A | P27815 | 1/20 | 0.66 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.66 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | PDE5A | O76074 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15057965 | 0.85 | ALDH1A1 (0.64) | PGRPDE4BPDE3APDE4APDE4C | |
| SCHEMBL4718997 | 0.83 | PDE4B (0.71) | PGRPDE4BPDE3APDE4APDE4C | |
| SCHEMBL4055845 | 0.82 | PGR (0.57) | PGRPDE4BPDE3APDE4APDE4C | |
| SCHEMBL11149657 | 0.79 | KMT2A (0.58) | PGRALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL31703214 | 0.79 | LMNA (0.67) | PGRALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL10205888 | 0.77 | LMNA (0.64) | PGRALDH1A1KMT2ALMNATP53 | |
| SCHEMBL11400866 | 0.77 | KMT2A (0.56) | PGRPDE4BALDH1A1KMT2AMEN1 | |
| SCHEMBL1758434 | 0.76 | KDM4E (0.72) | PGRPDE4BPDE3APDE4APDE4C | |
| SCHEMBL1757580 | 0.76 | KDM4E (0.56) | PGRPDE4BPDE3APDE4APDE4C | |
| SCHEMBL12773206 | 0.76 | LMNA (1.00) | PGRPDE4BPDE3APDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2063894-B1 | FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS FOR TREATING NEUROINFLAMMATORY DISEASES | UNIV NORTHWESTERN (US) | 2019-08-28 | — | — | EP | disclosed |
| EP-2604597-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF INHIBITOR OF PHOSPHODIESTERASE 10A | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-9408845-B2 | Formulations containing pyridazine compounds | NORTHWESTERN UNIVERSITY (US) | 2016-08-09 | — | — | US | disclosed |
| US-9150588-B2 | Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| EP-1812408-B1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | UNIV NORTHWESTERN (US) | 2013-10-09 | — | — | EP | disclosed |
| EP-2604597-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-20130137675-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-30 | — | — | US | disclosed |
| US-20130072496-A1 | FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS | NORTHWESTERN UNIVERSITY (US) | 2013-03-21 | — | — | US | disclosed |
| US-8367672-B2 | Pyridazine compounds, compositions and methods | UNIVERSITE DE STRASBOURG (FR) | 2013-02-05 | — | — | US | disclosed |
| US-8158627-B2 | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090325973-A1 | FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-31 | — | — | US | disclosed |
| US-20090197885-A1 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| EP-2063894-A2 | FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS FOR TREATING NEUROINFLAMMATORY DISEASES | The Regents Of Northwestern University (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080318899-A1 | Pyridazine Compounds, Compositions and Methods | UNIVERSITE DE STRASBOURG (FR) | 2008-12-25 | — | — | US | disclosed |
| WO-2007127375-A2 | FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS FOR TREATING NEUROINFLAMMATORY DISEASES | NORTHWESTERN UNIVERSITY (US) | 2007-11-08 | — | — | WO | disclosed |
| US-4404203-A | AND 6-PHENYL-4,5-DIHYDRO-3/2H/-PYRIDAZINONES | WARNER-LAMBERT COMPANY (US) | 1983-09-13 | — | — | US | disclosed |
| US-4397854-A | INCREASE IN MYOCARDIAL CONTRACTILITY | WARNER-LAMBERT COMPANY (US) | 1983-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325973-A1 | FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS | TST, SRMS, STS | PGR 1282/4885PDE4B 4845/4885PDE3A 3709/4885 |
| US-20130072496-A1 | FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS | TST, SRMS, STS | PGR 1041/4885PDE4B 4575/4885PDE3A 3593/4885 |
| US-20090197885-A1 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | ACHE, BCHE, BACE1 | PGR 1423/4885PDE4B 597/4885PDE3A 566/4885 |
| US-20080318899-A1 | Pyridazine Compounds, Compositions and Methods | APP, PSEN1, PSEN2 | PGR 608/4885PDE4B 734/4885PDE3A 1131/4885 |
| US-20130137675-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | PDE3A, PDE2A, PDE5A | PGR 3204/4885PDE4B 5/4885PDE3A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.